The University of Southampton
University of Southampton Institutional Repository

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma
Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma
The mechanisms of interaction between anti-CD40 monoclonal antibody (mAb) therapy and external beam irradiation were investigated in 2 syngeneic B-cell lymphoma models. We have established doses of anti-CD40 mAb and irradiation which, although ineffective when given singly, were capable of providing long-term protection when used in combination. Furthermore, such treatment was not only critically dependent on the dose of mAb and irradiation but also on tumor load, with greater efficacy only occurring at higher tumor burden. Using blocking antibody, the potency of treatment was shown to be totally dependent on CD8+ T cells, with protective levels of CD8+ cells occurring only in mice receiving the combination of anti-CD40 and irradiation. Interestingly, the ratio of T cells (CD8+) to tumor cells in mice receiving combination treatment was between 10 and 15 times that seen in animals given anti-CD40 or irradiation alone. In vivo tracking experiments revealed a 2-phase decrease in tumor burden, the first resulting directly from the external irradiation and the second, occurring 5 days later, concomitant with the rise in tumor-specific CD8+ cells. We suggest that the external irradiation induced an initial kill of lymphoma cells, probably by apoptosis, which releases tumor antigens and slows the progression of the malignancy to allow generation of a curative cytotoxic T lymphocyte (CTL) response promoted by the anti-CD40 mAb. Combining irradiation with immunomodulatory mAb as described here appears to provide a powerful new approach to the management of cancer.
0006-4971
1449-1457
Honeychurch, Jamie
4ecce821-9d37-4c35-bcb3-871ff832a3d2
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Johnson, Peter W.M.
1a86c9a9-25b4-4529-9353-d14fd062d63b
Illidge, Timothy M.
003bddd7-d778-4c77-bcaa-3b71b364d9a1
Honeychurch, Jamie
4ecce821-9d37-4c35-bcb3-871ff832a3d2
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Johnson, Peter W.M.
1a86c9a9-25b4-4529-9353-d14fd062d63b
Illidge, Timothy M.
003bddd7-d778-4c77-bcaa-3b71b364d9a1

Honeychurch, Jamie, Glennie, Martin J., Johnson, Peter W.M. and Illidge, Timothy M. (2003) Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood, 102 (4), 1449-1457. (doi:10.1182/blood-2002-12-3717.).

Record type: Article

Abstract

The mechanisms of interaction between anti-CD40 monoclonal antibody (mAb) therapy and external beam irradiation were investigated in 2 syngeneic B-cell lymphoma models. We have established doses of anti-CD40 mAb and irradiation which, although ineffective when given singly, were capable of providing long-term protection when used in combination. Furthermore, such treatment was not only critically dependent on the dose of mAb and irradiation but also on tumor load, with greater efficacy only occurring at higher tumor burden. Using blocking antibody, the potency of treatment was shown to be totally dependent on CD8+ T cells, with protective levels of CD8+ cells occurring only in mice receiving the combination of anti-CD40 and irradiation. Interestingly, the ratio of T cells (CD8+) to tumor cells in mice receiving combination treatment was between 10 and 15 times that seen in animals given anti-CD40 or irradiation alone. In vivo tracking experiments revealed a 2-phase decrease in tumor burden, the first resulting directly from the external irradiation and the second, occurring 5 days later, concomitant with the rise in tumor-specific CD8+ cells. We suggest that the external irradiation induced an initial kill of lymphoma cells, probably by apoptosis, which releases tumor antigens and slows the progression of the malignancy to allow generation of a curative cytotoxic T lymphocyte (CTL) response promoted by the anti-CD40 mAb. Combining irradiation with immunomodulatory mAb as described here appears to provide a powerful new approach to the management of cancer.

This record has no associated files available for download.

More information

Published date: 2003

Identifiers

Local EPrints ID: 26386
URI: http://eprints.soton.ac.uk/id/eprint/26386
ISSN: 0006-4971
PURE UUID: 5b40fd63-6161-4480-85aa-fa89b49ad45f

Catalogue record

Date deposited: 19 Apr 2006
Last modified: 15 Mar 2024 07:10

Export record

Altmetrics

Contributors

Author: Jamie Honeychurch
Author: Peter W.M. Johnson
Author: Timothy M. Illidge

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×